© 2015 CTx CRC Pty Ltd
CTx CEO announces that the majority of its current partners have chosen to reinvest their share of the recent cash distribution from CTx back into the organisation following major licensing deal.
Our job is to discover promising new small molecule drug compounds and advance them through the high risk early phases of drug development.
Cancer Therapeutics CRC and its commercialisation partner Cancer Research Technology (CRT) are pleased to announce a licensing deal with MSD, known as Merck in the US and Canada, to develop inhibitors of protein arginine methyltransferase 5 (PRMT5).
Our research and development platform spans the full range of technologies required to discover small molecule hits and develop them to clinical candidates. Critically, each of our novel drug discovery projects is underpinned by leading medical researchers with cutting edge expertise in the target biology.
By providing an integrated and coherent pathway for drug discovery, commercialisation and clinical development, CTx is at the forefront of delivering more effective cancer drugs to market.
All our discovery projects are managed and scrutinised by a Project Leaders Group and an independent group of experts as part of our CTx Scientific Advisory Group.